Deutsch English Français

Contact

EP2533778

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2533778

EP2533778 - TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 26.12.2014 Database last updated on 19.10.2024
Most recent event Tooltip	26.12.2014	Application deemed to be withdrawn	published on 28.01.2015 [2015/05]
Applicant(s)	For all designated states Lexicon Pharmaceuticals, Inc. 8800 Technology Forest Place The Woodlands, TX 77381 / US
	[2012/51]
Inventor(s)	01 / SANDS, Arthur Thomas Lexicon Pharmaceuticals Inc. 8800 Technology Forest Place The Woodlands, Texas 77381 / US
	[2012/51]
Representative(s)	Hewson, Timothy John, et al Abel & Imray 20 Red Lion Street London WC1R 4PQ / GB
	[N/P]
Former [2012/51]	Hewson, Timothy John, et al Abel & Imray 20 Red Lion Street London, WC1R 4PQ / GB
Application number, filing date	11705103.7	09.02.2011
	WO2011US24141
Priority number, date	US20100303002P	10.02.2010 Original published format: US 303002 P
	[2012/51]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2011100285
	Date:	18.08.2011
	Language:	EN
	[2011/33]
	Type:	A1 Application with search report
	No.:	EP2533778
	Date:	19.12.2012
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 18.08.2011 takes the place of the publication of the European patent application.
	[2012/51]
Search report(s)	International search report - published on:	EP	18.08.2011
Classification	IPC:	A61K31/4045, A61K31/4192, A61K31/497, A61K31/506, A61K45/06, A61P35/04	[2012/51]
	CPC:	A61K31/506 (EP,US); A61K31/197 (US); A61K31/4045 (EP,US); A61K31/405 (US); A61K31/4192 (EP,US); A61K31/4965 (US); (+) A61K31/497 (EP,US); A61K31/505 (US); A61K31/53 (US); A61K31/5377 (US); A61K45/06 (EP,US); A61P19/08 (EP); A61P35/04 (EP); A61P43/00 (EP); C07C229/16 (US); C07D239/34 (US); C07D239/42 (US); C07D239/47 (US); C07D241/20 (US); C07D241/24 (US); C07D249/06 (US); C07D251/18 (US); C07D251/52 (US); C07D401/04 (US); C07D403/04 (US); C07D403/12 (US); C07D409/10 (US) (-)
	C-Set:	A61K31/4045, A61K2300/00 (EP,US); A61K31/4192, A61K2300/00 (US,EP); A61K31/497, A61K2300/00 (US,EP); A61K31/506, A61K2300/00 (US,EP)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2012/51]
Title	German:	TRYPTOPHANHYDROXYLASEHEMMER ZUR BEHANDLUNG VON KNOCHENMETASTASEN	[2012/51]
	English:	TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE	[2012/51]
	French:	INHIBITEURS DE LA TRYPTOPHANE HYDROXYLASE POUR LE TRAITEMENT DE LA MALADIE OSSEUSE MÉTASTATIQUE	[2012/51]
Entry into regional phase	04.09.2012	National basic fee paid
	04.09.2012	Designation fee(s) paid
	04.09.2012	Examination fee paid
Examination procedure	04.09.2012	Examination requested [2012/51]
	12.04.2013	Amendment by applicant (claims and/or description)
	11.04.2014	Despatch of a communication from the examining division (Time limit: M04)
	22.08.2014	Application deemed to be withdrawn, date of legal effect [2015/05]
	19.09.2014	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2015/05]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 11.04.2014
Fees paid	Renewal fee
	12.02.2013	Renewal fee patent year 03
	12.02.2014	Renewal fee patent year 04
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[A]WO2009002964 (LEXICON PHARMACEUTICALS INC [US], et al) [A] 1-11 * claims 1-24 *;
		[A]WO2009014972 (LEXICON PHARMACEUTICALS INC [US], et al) [A] 1-11 * claims 1-20 *;
		[A]WO2008073933 (LEXICON PHARMACEUTICALS INC [US], et al) [A] 1-11 * claims 1-53 *
	by applicant	US2007191370
		US7553840
		US2004164194
		US2004195413
		US2004251332
		US2005042177
		US2005031691
		US5145684
		US5510118
		US5518187
		US5534270
		US5543133
		US5662883
		US5665331
		US5718388
		US5718919
		US5834025
		US5862999
		US6431478
		US6742734
		US6745962
		- WALTHER, D.J. ET AL., SCIENCE, (2003), vol. 299, page 76
		- YADAV, V.K. ET AL., CELL, (2008), vol. 135, pages 825 - 837
		- CREMATA, V.Y. ET AL., CLIN. PHARMACOL. THER., (1966), vol. 7, no. 6, pages 768 - 76
		- ENGELMAN, K. ET AL., NEW ENGL. J. MED., (1967), vol. 277, no. 21, pages 1103 - 1108
		- ALPINI, G. ET AL., CANCER RES., (2008), vol. 68, no. 22, page 9184
		- DIZEYI, N. ET AL., THE PROSTATE, (2004), vol. 59, pages 328 - 336
		- SIDDIQUI, E.J. ET AL., J. UROLOGY, (2006), vol. 176, pages 1648 - 1653
		- COLEMAN, R.E., CLINICAL CANCER RES., (2006), vol. 12, page 6243S
		- BARNI, S. ET AL., ANNALS ONCOLOGY, (2006), vol. 17, no. 2, pages II91 - II95
		- BROWN, S.A.; GUISE, T.A., CRIT REV EUKARYOT GENE EXPR., (2009), vol. 19, no. 1, pages 47 - 60,47
		- "Design and Application of Prodrugs", BUNDGAARD, H., A Textbook of Drug Design and Development, (1991), pages 113 - 191
		- BUNDGAARD, H., ADVANCED DRUG DELIVERY REVIEW, (1992), vol. 8, pages 1 - 38
		- WILEN, S. H. ET AL., TETRAHEDRON, (1977), vol. 33, page 2725
		- WILEN, S. H., Tables of Resolving Agents and Optical Resolutions, UNIV. OF NOTRE DAME PRESS, NOTRE DAME, (1972), page 268
		- RIANT, P. ET AL., JOURNAL OF NEUROCHEMISTRY, (1988), vol. 51, pages 421 - 425
		- KASTIN, A.J.; AKERSTROM, V., J. PHARMACOL. EXP. THERAPEUTICS, (2000), vol. 294, pages 633 - 636
		- W. A. BANKS, W.A. ET AL., J. PHARMACOL. EXP. THERAPEUTICS, (2002), vol. 302, pages 1062 - 1069
		- WILEN, S. H., Tables of Resolving Agents and Optical Resolutions, UNIV. OF NOTRE DAME PRESS, (1972), page 268
		- DAVIS; BREWSTER, NAT. REV. DRUG DISC., (2004), vol. 3, pages 1023 - 1034
		- RABINOW, NATURE REV. DRUG DISC., (2004), vol. 3, pages 785 - 796
		US20070638677

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p